stock watcher
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$EBYH is very undervalued and the float and outstanding and very conservative. This stock is the best long term play in the cannabis data and technology part of the industry. With the high probability that Schedule 1 goes to schedule 3 in 2024, Strainsforpains’ services and products will be in great demand.
Here is promo video, CEO audio, as well as video interview.
Here is the interview with the company CEO
$EBYH
Here are three news releases on company's progress
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
https://finance.yahoo.com/news/strainsforpains-inc-discusses-inspiration-app-140000889.html
Here is a YouTube video of a promo for company
Here are three news releases on company's progress
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
https://finance.yahoo.com/news/strainsforpains-inc-discusses-inspiration-app-140000889.html
Here is a YouTube video of a promo for company
$EBYH Strainsforpains showcased its CBD brand and database services at the Necann Maryland show.
Stock is very undervalued. The company is the only publicly traded OTC that has done 17 years of scientific research and development into cannabis for pain management. Its database is unique and its CEO has spent all these years collaborating with cannabis scientists in Israel-Canada-Europe. They are now in high demand since we all know that Cannabis for medical research, at the very least, will go from Schedule 1 to 3 this year.
https://necann.com/maryland/
https://www.linkedin.com/posts/necann_strainsforpains-proprietary-strain-database-activity-7191176566993747969-XvQ-/
https://www.instagram.com/necannacon/p/C6gvuLCtyTr/
https://www.facebook.com/necanncon/
https://twitter.com/NE_CANN/status/1786420202122735686/photo/1
$EBYH Strainsforpains showcased its CBD brand and database services at the Necann Maryland show.
Stock is very undervalued.
https://necann.com/maryland/
https://www.linkedin.com/posts/necann_strainsforpains-proprietary-strain-database-activity-7191176566993747969-XvQ-/
https://www.instagram.com/necannacon/p/C6gvuLCtyTr/
https://www.facebook.com/necanncon/
https://twitter.com/NE_CANN/status/1786420202122735686/photo/1
$EBYH Strainsforpains showcased its CBD brand and database services at the Necann Maryland show.
Stock is very undervalued.
https://necann.com/maryland/
https://www.linkedin.com/posts/necann_strainsforpains-proprietary-strain-database-activity-7191176566993747969-XvQ-/
https://www.instagram.com/necannacon/p/C6gvuLCtyTr/
https://www.facebook.com/necanncon/
https://twitter.com/NE_CANN/status/1786420202122735686/photo/1
$EBYH Strainsforpains showcased its CBD brand and database services at the Necann Maryland show.
Stock is very undervalued.
https://necann.com/maryland/
https://www.linkedin.com/posts/necann_strainsforpains-proprietary-strain-database-activity-7191176566993747969-XvQ-/
https://www.instagram.com/necannacon/p/C6gvuLCtyTr/
https://www.facebook.com/necanncon/
https://twitter.com/NE_CANN/status/1786420202122735686/photo/1
$EBYH Strainsforpains showcased its CBD brand and database services at the Necann Maryland show.
Stock is very undervalued.
https://necann.com/maryland/
https://www.linkedin.com/posts/necann_strainsforpains-proprietary-strain-database-activity-7191176566993747969-XvQ-/
https://www.instagram.com/necannacon/p/C6gvuLCtyTr/
https://www.facebook.com/necanncon/
https://twitter.com/NE_CANN/status/1786420202122735686/photo/1
Strainsforpains showcased its CBD brand and database services at the Necann Maryland show.
Stock is very undervalued.
https://necann.com/maryland/
https://www.linkedin.com/posts/necann_strainsforpains-proprietary-strain-database-activity-7191176566993747969-XvQ-/
https://www.instagram.com/necannacon/p/C6gvuLCtyTr/
https://www.facebook.com/necanncon/
https://twitter.com/NE_CANN/status/1786420202122735686/photo/1
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content
NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023.
First quarter 2024 shows $130,000 in orders. I expect over 1 million in 2024 sales for the CBD division alone. The management is showcasing its products and services at numerous shows this year ( Benzinga Miami, Javits Center NYC, etc.)
$EBYH
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content
NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023. The company has announced that its
first quarter 2024 has seen a $130,000 order for its CBD products as well.
Mr. Shainberg, Strainsforpains president stated that “We anticipate 2024 to be a milestone year for
us, not just with major increases in revenues, but also joint ventures in developments of new
products, licensing agreements, upgrade to our pain management app utilizing the latest in
artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations
for manufacturing and distribution of CBD products”.
The company is working with scientists and doctors well known in their fields, in areas of water
solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered
into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission
is to develop the next generation of anti-inflammatory drugs.
Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its
upcoming audited financials within 2024.
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content
NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023. The company has announced that its
first quarter 2024 has seen a $130,000 order for its CBD products as well.
Mr. Shainberg, Strainsforpains president stated that “We anticipate 2024 to be a milestone year for
us, not just with major increases in revenues, but also joint ventures in developments of new
products, licensing agreements, upgrade to our pain management app utilizing the latest in
artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations
for manufacturing and distribution of CBD products”.
The company is working with scientists and doctors well known in their fields, in areas of water
solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered
into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission
is to develop the next generation of anti-inflammatory drugs.
Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its
upcoming audited financials within 2024.
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content
NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023. The company has announced that its
first quarter 2024 has seen a $130,000 order for its CBD products as well.
Mr. Shainberg, Strainsforpains president stated that “We anticipate 2024 to be a milestone year for
us, not just with major increases in revenues, but also joint ventures in developments of new
products, licensing agreements, upgrade to our pain management app utilizing the latest in
artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations
for manufacturing and distribution of CBD products”.
The company is working with scientists and doctors well known in their fields, in areas of water
solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered
into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission
is to develop the next generation of anti-inflammatory drugs.
Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its
upcoming audited financials within 2024.
$EBYH Strainsforpains, Inc. News, small float, 200k CBD revenues past 90 days.
CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and #StrategicPartnership and #Research Potential with GenBio Inc.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
https://www.instagram.com/strains_for_pains/
$EBYH Strainsforpains, Inc. News, small float, 200k CBD revenues past 90 days.
CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and #StrategicPartnership and #Research Potential with GenBio Inc.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
https://www.instagram.com/strains_for_pains/
$EBYH Strainsforpains, Inc. News, small float, 200k CBD revenues past 90 days.
CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and #StrategicPartnership and #Research Potential with GenBio Inc.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH NEWS......... Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH NEWS......... Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH NEWS......... Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH NEWS......... Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH -- Strainsforpains CEO Simon Shainberg Discusses Entering 191 Billion Dollar Anti-Inflammatory Market, and Strategic Partnership and Research Potential with GenBio Corp.
https://finance.yahoo.com/news/strainsforpains-ceo-simon-shainberg-discusses-120000687.html
$EBYH I expect a breakout . Small float.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
https://www.instagram.com/strains_for_pains/
https://www.linkedin.com/company/strainsforpains/?viewAsMember=true
https://audioboom.com/posts/8466160-strainsforpains-inc-discusses-inspiration-app-technology-and-cbd-market-entrance-with-the-stoc
$EBYH I expect a breakout . Small float.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
https://www.instagram.com/strains_for_pains/
https://www.linkedin.com/company/strainsforpains/?viewAsMember=true
https://audioboom.com/posts/8466160-strainsforpains-inc-discusses-inspiration-app-technology-and-cbd-market-entrance-with-the-stoc
$EBYH Dramatically increased in revenues. Last chance at these prices.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
$EBYH Dramatically increased in revenues.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap.
$EBYH The company has dramatically increased in revenues. Expect major news on telehealth.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap.
$EBYH The company has dramatically increased in revenues. Expect major news on telehealth.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap.
$EBYH
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap.
$EBYH
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap. Look for a breakout next week.
$EBYH
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap. Look for a breakout next week.
$EBYH
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
This is the last chance to get in so cheap.
https://finance.yahoo.com/news/strainsforpains-inc-investors-strainsforpains-inc-130000775.html
$EBYH is going to rock in 2024. This is the last chance to get in so cheap.
$EBYH low float, news coming out weekly now
https://finance.yahoo.com/news/strainsforpains-inc-discusses-inspiration-app-140000889.html
$EBYH
https://finance.yahoo.com/news/strainsforpains-inc-discusses-inspiration-app-140000889.html
"In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products. We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app."
$EBYH
https://finance.yahoo.com/news/strainsforpains-inc-discusses-inspiration-app-140000889.html
"In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products. We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app."
https://finance.yahoo.com/news/strainsforpains-inc-discusses-inspiration-app-140000889.html
"In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products. We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app."